Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK), AbbVie Inc (ABBV): Will This HIV Triumph Change History?

Last year will long be remembered for its remarkable advances in the diagnosis and prevention of HIV; OraSure Technologies gained FDA approval for the first-ever at-home, over-the-counter, and needle-free HIV test, while Gilead Sciences, Inc. (NASDAQ: GILD)‘s drug Truvada, a therapeutic initially prescribed only for HIV-positive patients, was approved as a prophylactic medication for at-risk individuals.

But now, just months into 2013, a landmark discovery in the treatment — rather than prevention — of HIV has been announced.

Pfizer Inc. (NYSE:PFE)Public health phenomenon
Late Sunday evening, a number of media outlets reported that a child who had been infected with HIV at birth in 2010 had been cured following a course of treatment that lasted only a year and a half. According to the physicians involved in the infant’s care, a mixture of three drugs — commonly referred to as a “cocktail” — was administered to the infant just 30 hours after birth.

There have been varying reports as to the exact combination that was used, but an article published by Bloomberg stated that two drugs made by a Pfizer Inc. (NYSE:PFE) and GlaxoSmithKline plc (ADR) (NYSE:GSK) joint venture — lamivudine and zidovudine — along with AbbVie Inc (NYSE:ABBV)‘s Kaletra formed the treatment.The newborn was kept on the drugs for only 18 months and, for reasons that are still unclear, was not treated for the next 10 months. Miraculously, after relocating the child, doctors could not find any evidence that the patient was still infected with the disease.

The limited data available today suggests that it was the swift intervention of the doctors involved in this infant’s care that made the difference; administering this drug cocktail as soon after birth as possible, rather than days or weeks afterwards, could be the key to curing HIV-positive newborns.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.